Lung Cancer Diagnostics Market

Lung Cancer Diagnostics Market by Types (Small Cell Lung Cancer and Non-small Cell Lung Cancer), Tests (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1753
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 195
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global lung cancer diagnostics market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of cancer as well as development of innovative diagnostic kits and treatment methods.

Lung Cancer Diagnostics Market Key Takeaways

Lung cancer diagnosis refers to a screening procedure for detecting the cancer formation near and at the lungs, which is helpful for the treatment of the disease. Some of the key techniques for lung cancer treatment including imaging, cytology testing, biopsy, and tumor screening. Market expansion of lung cancer diagnostics is aided by rapid introduction of technological advancements in the field of tumor diagnosis. The need for more effective diagnostic systems arises from the fact that only 15% of lung cancer cases are diagnosed, while the remaining undiscovered cases progress to more aggressive forms. This result to lowering the 5-year survival rate to only 4% in patients diagnosed with late-stage lung cancer. The frequency of smoking has increased the chance of cancer dramatically in the developing world, which is predicted to have an impact on lung cancer incidence rates in the coming years. The need for early cancer screening and diagnosis is directly related to market growth as the prevalence of cancer rises.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing public awareness regarding the benefits regarding early diagnosis due to rising occurrence of cancer among a large number of population globally is expected to fuel the market growth in the coming years.
  • Raising funding for R&D activities from private and government bodies to develop better tumour diagnostic tools is anticipated to propel the market growth during the forecast period.
  • Introduction of innovative technology and improvement of treatment techniques that improve accuracy in result are estimated to drive the market growth during the forecast period.
  • High cost of the diagnosis and treatment of lung cancer and long treatment duration are key restraining factors projected to hamper the market growth.

Scope of the Report

The report on the global lung cancer diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Lung Cancer Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Small Cell Lung Cancer and Non-small Cell Lung Cancer) and Tests (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Roche Diagnostics; bioMérieu; Qiagen N.V.; Agilent Technologies; Thermo Fisher Scientific; AstraZeneca plc; Illumina Inc.; Janssen Pharmaceuticals, Inc.; and Sanofi S.A.

Market Segment Insights

Non-small cell lung cancer segment is projected to account for a key market share

Based on types, the lung cancer diagnostics market is bifurcated into small cell lung cancer and non-small cell lung cancer. The non-small cell lung cancer segment is expected to account for a key share of the market during the forecast period owing to rising case of large tumor size. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all cancer cases. Large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other are less common kinds of NSCLC and are among the different subtypes of NSCLC. Meanwhile, the small cell lung cancer (SCLC) segment is anticipated to exhibit a high CAGR during the forecast period as the disease type spreads swiftly throughout the body easily. The small cell lung tumors segment accounted for just around 10% of the global cancers diagnosis. SCLC is divided into two types: small-cell lung carcinoma and mixed small-cell lung cancer.

Lung Cancer Diagnostics Market By Types

Molecular test segment is expected to grow at a rapid pace

On the basis of tests, the market is divided into imaging test, biopsy, sputum cytology, molecular test, and others. The molecular test segment is expected to expand at a rapid pace during the forecast period owing to new diagnostic test applications that have emerged as a result of improvements and innovations in molecular diagnostic technology. The imaging tests segment, on the other hand, held a large market share in 2020 and is anticipated to grow significantly in the coming years owing to the widespread use of various imaging techniques such as MRI, CT scan, and X-ray as primary cancer screening tools. Imaging studies are useful throughout the treatment period and act as an initial screening tool for lung cancer diagnosis. Lung cancer molecular tests allow for more tailored treatment. Specific proteins, genes, and other tumor-specific components known as mutations, including as EGFR, BRAF, ALK, ROS1, HER2, and RET, are identified with these assays.

Asia Pacific is anticipated to dominate the market

On the basis of regions, the global lung cancer diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period owing to the high market penetration rates of technologically advanced goods, increased patient awareness, and rising smoking prevalence levels in the region. However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rising penetration of advanced lung cancer diagnostic tools coupled with the rising awareness about the diseases symptoms.

Segments

Segments Covered in the Report
The global lung cancer diagnostics market has been segmented on the basis of

Types
  • Small Cell Lung Cancer
  • Non-small Cell Lung Cancer
Tests
  • Imaging Test
  • Biopsy
  • Sputum Cytology
  • Molecular Test
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Roche Diagnostics
  • bioMérieu
  • Qiagen N.V.
  • Agilent Technologies
  • Thermo Fisher Scientific
  • AstraZeneca plc
  • Illumina Inc.
  • Janssen Pharmaceuticals, Inc.
  • Sanofi S.A.

Competitive Landscape

Key players competing in the global lung cancer diagnostics market are Roche Diagnostics; bioMérieu; Qiagen N.V.; Agilent Technologies; Thermo Fisher Scientific; AstraZeneca plc; Illumina Inc.; Janssen Pharmaceuticals, Inc.; and Sanofi S.A. These market participants are implementing a primary strategy of mergers and acquisitions with the goal of covering large distribution territories and developing unique products. For example, as part of the personalised medicine strategy, Illumina worked with pharma giants Janssen Pharmaceuticals Inc., AstraZeneca plc, and Sanofi S.A. to develop gene sequencing tools for the detection of lung cancer. Furthermore, increasing research and development efforts to improve existing cancer detection tools is predicted to be a game-changing decision for end-users including hospitals and clinical laboratories.

Lung Cancer Diagnostics Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lung Cancer Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Lung Cancer Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Lung Cancer Diagnostics Market - Supply Chain
  4.5. Global Lung Cancer Diagnostics Market Forecast
     4.5.1. Lung Cancer Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Lung Cancer Diagnostics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Lung Cancer Diagnostics Market Absolute $ Opportunity
5. Global Lung Cancer Diagnostics Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Lung Cancer Diagnostics Market Size and Volume Forecast by Types
     5.3.1. Small Cell Lung Cancer Non-small Cell Lung Cancer
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Lung Cancer Diagnostics Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Lung Cancer Diagnostics Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Lung Cancer Diagnostics Demand Share Forecast, 2019-2026
7. North America Lung Cancer Diagnostics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Lung Cancer Diagnostics Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Lung Cancer Diagnostics Market Size and Volume Forecast by Types
     7.4.1. Small Cell Lung Cancer Non-small Cell Lung Cancer
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Lung Cancer Diagnostics Demand Share Forecast, 2019-2026
8. Latin America Lung Cancer Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Lung Cancer Diagnostics Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Lung Cancer Diagnostics Market Size and Volume Forecast by Types
     8.4.1. Small Cell Lung Cancer Non-small Cell Lung Cancer
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Lung Cancer Diagnostics Demand Share Forecast, 2019-2026
9. Europe Lung Cancer Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Lung Cancer Diagnostics Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Lung Cancer Diagnostics Market Size and Volume Forecast by Types
     9.4.1. Small Cell Lung Cancer Non-small Cell Lung Cancer
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Lung Cancer Diagnostics Demand Share Forecast, 2019-2026
10. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Lung Cancer Diagnostics Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Lung Cancer Diagnostics Market Size and Volume Forecast by Types
     10.4.1. Small Cell Lung Cancer Non-small Cell Lung Cancer
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Lung Cancer Diagnostics Demand Share Forecast, 2019-2026
11. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Lung Cancer Diagnostics Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Lung Cancer Diagnostics Market Size and Volume Forecast by Types
     11.4.1. Small Cell Lung Cancer Non-small Cell Lung Cancer
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Lung Cancer Diagnostics Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Lung Cancer Diagnostics Market: Market Share Analysis
  12.2. Lung Cancer Diagnostics Distributors and Customers
  12.3. Lung Cancer Diagnostics Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Roche Diagnostics bioMérieu Qiagen N.V. Agilent Technologies Thermo Fisher Scientific AstraZeneca plc  
Segments Covered in the Report
The global lung cancer diagnostics market has been segmented on the basis of

Types
  • Small Cell Lung Cancer
  • Non-small Cell Lung Cancer
Tests
  • Imaging Test
  • Biopsy
  • Sputum Cytology
  • Molecular Test
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Roche Diagnostics
  • bioMérieu
  • Qiagen N.V.
  • Agilent Technologies
  • Thermo Fisher Scientific
  • AstraZeneca plc
  • Illumina Inc.
  • Janssen Pharmaceuticals, Inc.
  • Sanofi S.A.

Key players competing in the global lung cancer diagnostics market are Roche Diagnostics; bioMérieu; Qiagen N.V.; Agilent Technologies; Thermo Fisher Scientific; AstraZeneca plc; Illumina Inc.; Janssen Pharmaceuticals, Inc.; and Sanofi S.A. These market participants are implementing a primary strategy of mergers and acquisitions with the goal of covering large distribution territories and developing unique products. For example, as part of the personalised medicine strategy, Illumina worked with pharma giants Janssen Pharmaceuticals Inc., AstraZeneca plc, and Sanofi S.A. to develop gene sequencing tools for the detection of lung cancer. Furthermore, increasing research and development efforts to improve existing cancer detection tools is predicted to be a game-changing decision for end-users including hospitals and clinical laboratories.

Lung Cancer Diagnostics Market By Key Players

Buy Report